← Leaderboards
Stephen K Tyring
University Of Texas Medical Br Galveston
$3,207,560
Attributed
$3,207,560
Total exposure
9
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$3,207,560 · 9
By mechanism
M01$3,066,588 · 8
R03$140,972 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Medical Br Galveston
Same institution · by research overlap
- Lawrence R Stanberry$4,793,012
- Carmen Radecki Breitkopf$4,245,285
- Lee-Jane W Lu$7,395,875
- Nigel Bourne$10,520,495
- Patricia Lee$34,211
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationDrug Screening /EvaluationClinical Trial Phase IMicroorganism Disease ChemotherapyAntiviral AgentsOral AdministrationShinglesAcyclovirPlacebosGenital HerpesProdrugsSensory DiscriminationAdult Human (21+)Medical ComplicationDrug Adverse EffectLongitudinal Human StudyHuman Middle Age (35-64)Quality Of LifeSelf HelpChronic PainPharmacokineticsCommunicable Disease Control
Grant awards (20)
Genetic Resistance to Oncogenic Human Papillomaviruses$69,910
R03 · FY2004 · CA
Genetic Resistance to Oncogenic Human Papillomaviruses$71,062
R03 · FY2003 · CA
VALACYCLOVIR THERAPY OF SHINGLES IN IMMUNOCOMPROMISED PATIENTS$279,290
M01 · FY2002 · RR
VALACYCLOVIR THERAPY OF SHINGLES IN IMMUNOCOMPETENT PATIENTS$279,290
M01 · FY2002 · RR
STUDY OF ORAL LOBUCAVIR IN PATIENTS WITH RECURRENT GENITAL HERPES$279,290
M01 · FY2002 · RR
ABT 606 VS ACYCLOVIR FOR TREATMENT OF HERPES ZOSTER$279,290
M01 · FY2002 · RR
EFFICACY OF HERPES SIMPLEX VACCINE--GD2T WITH MPL TO PREVENT GENITAL HERPES$279,290
M01 · FY2002 · RR
VALACYCLOVIR THERAPY OF SHINGLES IN IMMUNOCOMPETENT PATIENTS$279,290
M01 · FY2001 · RR
EFFICACY OF HERPES SIMPLEX VACCINE--GD2T WITH MPL TO PREVENT GENITAL HERPES$279,290
M01 · FY2001 · RR
STUDY OF ORAL LOBUCAVIR IN PATIENTS WITH RECURRENT GENITAL HERPES$279,290
M01 · FY2001 · RR
VALACYCLOVIR THERAPY OF SHINGLES IN IMMUNOCOMPROMISED PATIENTS$279,290
M01 · FY2001 · RR
ABT 606 VS ACYCLOVIR FOR TREATMENT OF HERPES ZOSTER$279,290
M01 · FY2001 · RR
EFFICACY OF HERPES SIMPLEX VACCINE--GD2T WITH MPL TO PREVENT GENITAL HERPES$34,211
M01 · FY2000 · RR
ABT 606 VS ACYCLOVIR FOR TREATMENT OF HERPES ZOSTER$34,211
M01 · FY2000 · RR
VALACYCLOVIR THERAPY OF SHINGLES IN IMMUNOCOMPROMISED PATIENTS$34,211
M01 · FY2000 · RR
VALACYCLOVIR THERAPY OF SHINGLES IN IMMUNOCOMPETENT PATIENTS$34,211
M01 · FY2000 · RR
STUDY OF ORAL LOBUCAVIR IN PATIENTS WITH RECURRENT HERPES LABIALIS$34,211
M01 · FY2000 · RR
STUDY OF ORAL LOBUCAVIR IN PATIENTS WITH RECURRENT GENITAL HERPES$34,211
M01 · FY2000 · RR
EFFICACY OF HERPES SIMPLEX VACCINE WITH MPL TO PREVENT GENITAL HERPES$34,211
M01 · FY2000 · RR
PERCUTANEOUS PENETRATION OF IMIQUIMOD FOR TREATMENT OF GENITAL WARTS$34,211
M01 · FY2000 · RR